about
Molecular pathways: not a simple tube--the many functions of blood vesselsFAK in cancer: mechanistic findings and clinical applicationsFocal adhesion kinase is required for synovial fibroblast invasion, but not murine inflammatory arthritisBreast cancer cells condition lymphatic endothelial cells within pre-metastatic niches to promote metastasisRuthenium polypyridyl complex inhibits growth and metastasis of breast cancer cells by suppressing FAK signaling with enhancement of TRAIL-induced apoptosis.The anti-tumor NC1 domain of collagen XIX inhibits the FAK/ PI3K/Akt/mTOR signaling pathway through αvβ3 integrin interaction.Focal adhesion kinase is a phospho-regulated repressor of Rac and proliferation in human endothelial cells.Molecular mechanisms underlying the antitumor activity of 3-aminopropanamide irreversible inhibitors of the epidermal growth factor receptor in non-small cell lung cancer.Multiple steps to activate FAK's kinase domain: adaptation to confined environments?Neuronal Wiskott-Aldrich syndrome protein regulates TGF-β1-mediated lung vascular permeabilitySynergy between a collagen IV mimetic peptide and a somatotropin-domain derived peptide as angiogenesis and lymphangiogenesis inhibitors.FAK contributes to proteinuria in hypercholesterolaemic rats and modulates podocyte F-actin re-organization via activating p38 in response to ox-LDLGenome-Wide Analysis of DNA Methylation in Hyperoxia-Exposed Newborn Rat Lung.Preclinical evaluation of the supercritical extract of azadirachta indica (neem) leaves in vitro and in vivo on inhibition of prostate cancer tumor growthControl of vascular permeability by adhesion molecules.Monitoring focal adhesion kinase phosphorylation dynamics in live cells.Focal adhesion kinase (FAK) siRNA inhibits human hypertrophic scar by suppressing integrin α, TGF-β and α-SMA.The role of placenta growth factor in the hyperoxia-induced acute lung injury in an animal model.Inhibition of cell migration by focal adhesion kinase: Time-dependent difference in integrin-induced signaling between endothelial and hepatoblastoma cells.The FAK inhibitor BI 853520 exerts anti-tumor effects in breast cancer
P2860
Q27025036-9907785B-6D4D-4637-BB41-041BFECCCE13Q27026533-3AAFC826-9C3B-4E4F-B2D0-6FA5C0B198C8Q34374676-69AF36D9-8D05-4AB7-B6DC-A54C99AB2E6CQ35154624-4CC7B556-E8ED-462F-9118-87A4B91BF5C3Q35183003-5AC8B0DA-1632-4F22-BE88-6DEDF096782FQ35856555-558FA030-F0CF-42CB-B743-382B57F7DE29Q36425657-FEA16D2B-CF0A-46D0-876C-5760DCDC8342Q36567573-353FF05C-FC2D-4971-B3F1-EDEFCAA463E9Q36903593-FC2F6354-4E0C-47BE-8C1E-0D75DFC314F1Q36996355-F06B09CC-E0D3-4F84-8EAF-D43E2D9841B7Q37401441-088F8ED9-C4D3-4265-ADDA-2B9610F0742BQ37662913-C477FEB2-5388-4C6A-8990-47682FE82D5FQ38688034-A39FC38D-31A0-4242-817A-393245C23EC1Q39011125-306B2BC7-09B5-4C01-AB23-7709A265BB74Q41856569-01AD8A19-6FF3-4B03-A8B1-17F4ADC0C0D8Q48314829-E13C0E27-876E-4557-8803-B398DFDBBD8BQ53066784-B3A66941-03D5-467E-A6E7-6002AD667ED1Q53666793-1B66ACAA-C908-495E-96AE-1A5B804601ECQ54124233-2CBC771C-FA05-428B-87D3-9071A5D1D8ABQ58712101-7EFCCC2D-C0DC-4004-9A05-12C2E9F6B5E3
P2860
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Endothelial FAK as a therapeutic target in disease.
@ast
Endothelial FAK as a therapeutic target in disease.
@en
type
label
Endothelial FAK as a therapeutic target in disease.
@ast
Endothelial FAK as a therapeutic target in disease.
@en
prefLabel
Endothelial FAK as a therapeutic target in disease.
@ast
Endothelial FAK as a therapeutic target in disease.
@en
P2860
P1476
Endothelial FAK as a therapeutic target in disease.
@en
P2093
Giovanni A Infusino
Jeffrey R Jacobson
P2860
P356
10.1016/J.MVR.2011.09.011
P577
2011-10-06T00:00:00Z